Beneficial neurohormonal profile of spironolactone in severe congestive heart failure
Results from the RALES neurohormonal substudy
Michel F. Rousseau, MD, PhD, FACC*,*,
Olivier Gurné, MD, PhD*,
Daniel Duprez, MD, PhD, FACC ,
Walter Van Mieghem, MD, PhD ,
Annie Robert, PhD ,
Sylvie Ahn*,
Laurence Galanti, MD, PhD*,
Jean-Marie Ketelslegers, MD, PhD|| Belgian RALES Investigators
* Division of Cardiology, University of Louvain, Brussels, Belgium
School of Public Health, University of Louvain, Brussels, Belgium
|| Diabetes and Nutrition Unit, University of Louvain, Brussels, Belgium
Cardiovascular Division, University of Minnesota, Minneapolis, Minnesota, USA
Hartcentrum Limburg, Genk, Belgium
View larger version (17K):
[in a new window]
|
Figure 1 Changes in plasma levels of brain natriuretic peptide (BNP) (expressed on a log scale) from baseline to three and six months in the placebo and spironolactone groups.
|
|
View larger version (17K):
[in a new window]
|
Figure 2 Changes in plasma levels of N-terminal portion of pro-atrial natriuretic factor (N-proANF) (expressed on a log scale) from baseline to three and six months in the placebo and spironolactone groups.
|
|
View larger version (17K):
[in a new window]
|
Figure 3 Changes in plasma levels of angiotensin II (AII) (expressed on a log scale) from baseline to three and six months in the placebo and spironolactone groups.
|
|
View larger version (18K):
[in a new window]
|
Figure 4 Changes in plasma levels of aldosterone (expressed on a log scale) from baseline to three and six months in the placebo and spironolactone groups.
|
|
|
